Article - 03/07/2018 The digital laboratory is picking up speed A new team at the Fraunhofer IPA is developing digital laboratory systems to support industrial partners in planning and managing laboratory processes. This benefits companies in terms of quality assurance, economic efficiency and, notably, ergonomic improvements to the work place.https://www.gesundheitsindustrie-bw.de/en/article/news/the-digital-laboratory-is-picking-up-speed
Dossier - 06/03/2018 Big data - the big promise of the new digitised world Big data is a widely used buzzword in today's information era. The use of big data in the digital world presents both an opportunity and a risk. Mass data is now used and analysed in almost all areas of life. Even the healthcare sector is undergoing extensive digitisation. https://www.gesundheitsindustrie-bw.de/en/article/dossier/big-data-the-big-promise-of-the-new-digitised-world
Diagnostics - 29/01/2018 New test for extended blood fat analysis Cholesterol is seen as the cause of atherosclerosis, a disease that can lead to heart attacks and strokes. However, it now seems that the way cholesterol is packaged may be even more important than high blood cholesterol levels. Nuclear magnetic resonance (NMR) spectroscopy now allows the high-throughput analysis of such lipid packages. https://www.gesundheitsindustrie-bw.de/en/article/news/new-test-for-extended-blood-fat-analysis
Press release - 12/12/2017 BRAIN AG and Mannheim University develop 3D skin models for health care and cosmetics Research collaboration in project M2Aind for new real-time and high-resolution screening technologies of 3D skin spheroids. Mannheim University of Applied Sciences builds on expertise in 3D cell culture and advanced live cell imaging. BRAIN contributes unique skin reporter cells, screening compound libraries and market knowledge. Review article in Journal of Cellular Biotechnology. https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-ag-and-mannheim-university-develop-3d-skin-models-for-health-care-and-cosmetics
Article - 19/06/2017 Eric Gottwald: innovative 3D cell culture systems for pharmaceutical testing Realistic alternatives to animal testing are more in demand than ever, especially in the drug development field. One possible solution is 3D cell cultures that possess the characteristics of the tissue from which they originate. Such systems were already developed at the Karlsruhe Institute of Technology (KIT) many years ago. Due to the huge demand for such systems, Prof. Dr. Eric Gottwald and two of his colleagues founded a company called…https://www.gesundheitsindustrie-bw.de/en/article/news/eric-gottwald-innovative-3d-cell-culture-systems-for-pharmaceutical-testing
Article - 07/06/2017 A gene that regulates body heat and fat storage Researchers from Heidelberg have shown that the organismal balance between heat production and energy storage is regulated by a gene called THADA. In animal experiments, knocking out the THADA gene leads to excessive food intake, obesity and sensitivity to cold. As humans spread throughout the world and settled in different climate zones, THADA was exposed to high selection pressure due to evolutionary adaptation. This explains why human…https://www.gesundheitsindustrie-bw.de/en/article/news/a-gene-that-regulates-body-heat-and-fat-storage
Press release - 02/06/2017 GATC to be part of Eurofins Group GATC, one of the leading sequencing provider will be a part of the Eurofins Group as of July 2017 to create the leading company in the worldwide sequencing market.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gatc-wird-ein-teil-der-eurofins-gruppe
Press release - 24/05/2017 High-Tech Gründerfonds (HTGF) invests in Reutlingen-based SIGNATOPE GmbH – Safe medications thanks to new test procedures High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing will be reduced while the drug…https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-tech-gruenderfonds-htgf-invests-in-reutlingen-based-signatope-gmbh-safe-medications-thanks-to-new-test-procedures
Article - 18/05/2017 ImmuStick – novel rapid test for identifying disease pathogens In some situations such as in the food and pharmaceutical industries or hospitals, a test to identify disease pathogens can be vital. At present, such tests are relatively time-consuming and can take hours or even days to produce results, depending on the pathogen. Scientists from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart are currently developing a rapid test called ImmuStick which is as easy to use…https://www.gesundheitsindustrie-bw.de/en/article/news/immustick-novel-rapid-test-for-identifying-disease-pathogens
Article - 31/03/2017 Bosch to enter the medical technology sector – start-up culture meets proven expertise Many of us have known the Bosch Group mainly as a technology company that is active in the automotive sector. Now, the multinational company is opening up a whole new field of business and is entering the medical technology market with a new subsidiary. Bosch Healthcare Solutions GmbH, which is headquartered in the city of Waiblingen, has developed an innovative breath analysis device that allows asthmatics to measure the severity of airway…https://www.gesundheitsindustrie-bw.de/en/article/news/bosch-to-enter-the-medical-technology-sector-start-up-culture-meets-proven-expertise
Article - 02/03/2017 Personalised antibiotics therapy: fewer antibiotic-resistant bacteria Antibiotics have long been used as all-purpose weapons against infectious diseases – too often and too early, as we now know. This tendency has caused many bacteria to become resistant to standard antibiotics. The search for new substance classes has proved quite difficult. Care must therefore be taken to use existing antibiotics prudently in order to reduce the number of bacteria becoming resistant to them in the long term. Researchers from…https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-antibiotics-therapy-fewer-antibiotic-resistant-bacteria
Article - 01/03/2017 foxySpec – an analysis system with huge potential for bioproduction and diagnostics The mass spectrometry-based foxySpec system enables the monitoring of gases and liquids simultaneously in real time. These simultaneous measurements make the system interesting for medical diagnostics applications. However, bioproduction can also benefit from foxySpec, which can also be used to measure a large number of products during the production process in real time, thus supporting smooth processes in fermenters. https://www.gesundheitsindustrie-bw.de/en/article/news/foxyspec-an-analysis-system-with-huge-potential-for-bioproduction-and-diagnostics
Article - 21/12/2016 For all types of tests: Signatope’s biomarker assays Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.https://www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
Article - 13/12/2016 Smart sensor technology from Ulm can do more than just breath analysis Detecting disease-specific molecules in human breath is technically feasible, but time-consuming and rather costly. "µbreath" could soon change this. The breath gas analysis device has all the necessary requirements for commercial success in the healthcare sector: it is compact, accurate, highly sensitive and fast. The chemist who developed µbreath, Prof. Boris Mizaikoff from Ulm University, and his partners are hoping to start…https://www.gesundheitsindustrie-bw.de/en/article/news/smart-sensor-technology-from-ulm-can-do-more-than-just-breath-analysis
Press release - 12/12/2016 Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-obtains-eib-debt-financing-totaling-up-to-eur-25-million-to-further-expand-its-diagnostic-platform
Retrospective Meet & Match Pharmaceutical Process Technology - 07/04/2016 Speed dating for Pharmaceutical Process Technology – a business flirt at Bosch The speed dating format is no longer just a popular and simple dating method for lonely hearts, but has also become a rewarding way for establishing new business contacts and connections quickly and efficiently. BIOPRO Baden-Württemberg chose speed networking, as speed dating is called in the corporate world, for its recent Meet & Match event on pharmaceutical process technology, which took place on 15th March 2016 with the support of Bosch…https://www.gesundheitsindustrie-bw.de/en/article/press-release/speed-dating-for-pharmaceutical-process-technology-a-business-flirt-at-bosch
Article - 04/04/2016 An intelligent system for the storage and controlled release of pharmaceutical substances A sophisticated reservoir that sits under the skin and dispenses precise quantities of drugs locally and at a particular point in time now exists. A junior research group from the University of Freiburg’s BrainLinks-BrainTools excellence cluster led by Dr. Maria Asplund and her doctoral student Christian Böhler from the Department of Microsystems Engineering (IMTEK) has developed a small storage system made of organic-inorganic hybrid material…https://www.gesundheitsindustrie-bw.de/en/article/news/an-intelligent-system-for-the-storage-and-controlled-release-of-pharmaceutical-substances
Article - 03/03/2016 Liquid biopsies – beacons of hope for cancer diagnosis? Researchers around the world, including researchers from the Freiburg University Medical Center, are working on developing simple blood tests, so-called liquid biopsies, that can be used to obtain accurate information about tumour staging and the progress of therapy. An international liquid biopsy symposium was held in Freiburg in October 2015 and has produced valuable insights.https://www.gesundheitsindustrie-bw.de/en/article/news/liquid-biopsies-beacons-of-hope-for-cancer-diagnosis
Article - 28/01/2016 Crowdsourcing initiative to tackle Alzheimer’s The BioMed X Innovation Center and the biopharmaceutical company AbbVie Deutschland GmbH & Co. KG have used crowdsourcing to set up a team of scientists from renowned international institutions to investigate new options for treating Alzheimer’s disease. The team are looking for targets in the metabolism of tau proteins and its pathological modifications that can be used to develop drugs to treat Alzheimer’s disease.https://www.gesundheitsindustrie-bw.de/en/article/news/crowdsourcing-initiative-to-tackle-alzheimers
Digitalisation - 10/12/2015 cubuslab helps laboratories to enter the digital era cubuslab, a start-up company that was spun off from the Karlsruhe Institute of Technology in March 2015, has developed a technology to connect different types of laboratory equipment, from precision balances to analytical instruments. The technology is aimed at automating workflows and connecting and storing data in an electronic laboratory notebook. https://www.gesundheitsindustrie-bw.de/en/article/news/cubuslab-helps-laboratories-to-enter-the-digital-era
Article - 30/11/2015 Bacterial MccA is better than other enzymes when it comes to reducing sulphites Dr. Bianca Hermann from the University of Freiburg specialises in multi-haem enzymes, and investigates the enzymes’ structure and reaction mechanisms. She has clarified the enzymes’ crystal structure and reaction mechanisms and found out why the bacterial MccA enzyme complex can reduce sulphur-containing substances such as sulphites up to a hundred times faster than other enzymes.https://www.gesundheitsindustrie-bw.de/en/article/news/bacterial-mcca-is-better-than-other-enzymes-when-it-comes-to-reducing-sulphites
Article - 17/11/2015 Novel hydrogels as functional materials In the ”NanoBioMater”project house, researchers from the University of Stuttgart are working to develop novel hydrogels with integrated biocompatible scaffold structures. Their aim is to make the materials suitable for producing innovative components for environmental and food analytics as well as medical applications. The hydrogels could potentially be used in diagnostic biosensors and the controlled release of medical compounds. https://www.gesundheitsindustrie-bw.de/en/article/news/novel-hydrogels-as-functional-materials
Article - 24/09/2015 New test system for detection of HPV-related oral cavity cancers The number of people suffering from oral or oropharyngeal cancer is rising steadily. The major cause of these cancers is human papillomaviruses (HPV) that colonise the oral cavity, where they are difficult to detect. QIAGEN Lake Constance GmbH from Stockach, in cooperation with Abviris Deutschland GmbH, has developed a new test system to improve the detection of oral HPV. This new system enables rapid and reliable quantitative detection of…https://www.gesundheitsindustrie-bw.de/en/article/news/new-test-system-for-detection-of-hpv-related-oral-cavity-cancers
Pharmaceutical research and life sciences profit from unique biosensor technology - 18/09/2015 Biametrics GmbH concludes financing round with 3.1 Million Euro Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biametrics-gmbh-concludes-financing-round-with-31-million-euro
Press release - 11/09/2015 Venneos raises seed round of 1 million euros Venneos GmbH is based in Stuttgart and develops a novel imaging system for the analysis of biological cells. A consortium of business angels and family offices, along with the High-Tech Gründerfonds and Max Planck Society invest in the company to develop a market-ready product and prepare the market entry of the first product generation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/venneos-raises-seed-round-of-1-million-euros